ribavirin

ribavirin. Ribavirin is a broad-spectrum antiviral medication used primarily in combination with other agents for treating chronic hepatitis C infection. It is a synthetic nucleoside analogue that interferes with viral RNA replication and messenger RNA synthesis. While its precise mechanism is multifaceted, its clinical use is now largely superseded by direct-acting antivirals, though it remains important in certain contexts.

Medical uses

Ribavirin's primary historical use was in combination with peginterferon alfa-2a or peginterferon alfa-2b for the treatment of chronic hepatitis C virus infection, particularly genotypes 1 and 4. It is also used, often via inhalation, for the treatment of severe respiratory syncytial virus infection in hospitalized infants and young children. Furthermore, it finds application in treating certain arenavirus infections, such as Lassa fever, and has been investigated for use against other viral hemorrhagic fevers like those caused by the Hantavirus. The World Health Organization includes it on its List of Essential Medicines.

Adverse effects

Significant adverse effects are common, particularly with oral administration for hepatitis C. The most serious is dose-dependent hemolytic anemia, which can be severe and may require dose reduction or discontinuation. Other frequent effects include fatigue, nausea, rash, pruritus, cough, and dyspnea. It is a potent teratogen and is contraindicated in pregnancy, requiring strict contraception protocols during and after therapy. Concomitant use with certain drugs like azathioprine can increase toxicity risks.

Pharmacology

Ribavirin is a prodrug that, upon cellular uptake, is phosphorylated by host adenosine kinase to its active triphosphate form. This metabolite inhibits viral RNA-dependent RNA polymerase of various viruses, including those from the Flaviviridae and Paramyxoviridae families. It also depletes intracellular guanosine triphosphate pools via inhibition of inosine monophosphate dehydrogenase, thereby impairing viral RNA synthesis. Its pharmacokinetics are complex, with extensive distribution and a long terminal half-life, requiring careful monitoring in patients with renal impairment.

History

Ribavirin was first synthesized in 1970 by researchers at ICN Pharmaceuticals, notably Joseph T. Witkowski and Roland K. Robins. Initial investigations showed broad antiviral activity in vitro. Its first major clinical application was as an inhaled treatment for respiratory syncytial virus in the 1980s. The landmark approval for use in hepatitis C came in 1998 following pivotal trials like the one leading to the approval of Rebetron. Research into its use against emerging viruses like SARS-CoV-1 and MERS-CoV has been conducted, though with limited success.

Society and culture

Ribavirin has been marketed under several brand names including Rebetol by Merck & Co., Copegus by Genentech, and Virazole for inhalation. Its high cost and significant side-effect profile during the interferon era of hepatitis C treatment were major societal burdens. The subsequent development of sofosbuvir and other direct-acting antivirals by companies like Gilead Sciences dramatically reduced the reliance on ribavirin in many regions. It remains a critical tool in outbreak settings for certain World Health Organization-designated priority diseases.

Category:Antiviral drugs Category:Hepatitis C Category:Nucleoside analogues